晚期早产期使用倍他米松后新生儿低血糖的机制:胎儿代谢效应是否起作用?
本研究为Eunice Kennedy Shriver国家儿童健康与人类发展研究所母胎医学单位网络晚期早产皮质类固醇试验的二次分析,纳入203对母婴(倍他米松组106例,安慰剂组97例)。倍他米松暴露与脐血C肽、胰岛素和瘦素水平升高相关,C肽和胰岛素水平高于第90百分位与新生儿低血糖(血糖<40 mg/dL)风险升高相关(调整比值比分别为3.16和6.42)。
要点
- 晚期早产期使用倍他米松与胎儿高胰岛素血症等代谢改变相关。
- 脐血C肽和胰岛素水平高于第90百分位与新生儿低血糖风险升高相关。
- 倍他米松与C肽、胰岛素和瘦素的关联在给药后12至24小时内分娩者中最强。
核心结论
- 晚期早产期使用倍他米松与胎儿代谢改变(如高胰岛素血症)相关,这些改变与新生儿低血糖风险升高3至6倍相关。
- 作者认为该机制可能与糖尿病孕妇所生新生儿的机制相似,但结果需进一步验证,且需针对胎儿代谢效应进一步研究以确定能否预防晚期早产皮质类固醇后的新生儿低血糖。
研究设计与样本
- 本研究为Eunice Kennedy Shriver国家儿童健康与人类发展研究所母胎医学单位网络晚期早产皮质类固醇试验的二次分析,该试验为随机对照试验,比较有晚期早产威胁的孕妇使用产前倍他米松与安慰剂(2010–2015年)。
- 纳入有储存脐带血血浆的母婴对,排除严重先天畸形,最终纳入203例参与者:倍他米松组106例(52%),安慰剂组97例(48%)。
- 检测脐带血血浆中的C肽、胰岛素、瘦素和胰岛素样生长因子结合蛋白1(IGFBP-1),并进行比较。
主要发现
- 203例中173例(85%)早产分娩,23例(11%)有妊娠期糖尿病;61例(30%)新生儿发生低血糖,其中倍他米松组35例(33%),安慰剂组26例(27%)。
- 倍他米松暴露与脐血C肽、胰岛素和瘦素水平升高相关,与IGFBP-1无关。
- 倍他米松与C肽、胰岛素和瘦素的关联在给药后12至24小时内分娩的参与者中最强。
- 脐血C肽水平高于第90百分位与新生儿低血糖风险升高相关(调整比值比3.16,95%置信区间1.08–9.24)。
- 脐血胰岛素水平高于第90百分位与新生儿低血糖风险升高相关(调整比值比6.42,95%置信区间2.11–19.60)。
关键数值与推荐
- 新生儿低血糖定义为血糖<40 mg/dL。
- 所有检验为双侧,统计学显著性定义为P<.05。
- 脐血C肽水平高于第90百分位与新生儿低血糖的调整比值比为3.16(95%置信区间1.08–9.24)。
- 脐血胰岛素水平高于第90百分位与新生儿低血糖的调整比值比为6.42(95%置信区间2.11–19.60)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出本分析结果需进一步验证。
- 作者指出需要针对本文所示胎儿代谢效应进一步研究,以确定能否预防晚期早产皮质类固醇后的新生儿低血糖风险增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE:: Betamethasone administration in the late preterm period(340/7–365/7 weeks’ gestation) not only reduces neonatal respiratory morbidity but also increases neonatal hypoglycemia through an uncertain mechanism. Based on data from pregnant individuals with diabetes, excessive amounts of maternal glucose can cross the placenta and cause fetal hyperinsulinemia, which can cause neonatal hypoglycemia at birth. Given that betamethasone can also increase maternal glucose levels, our objective was to explore the potential mechanisms for late preterm steroid-induced neonatal hypoglycemia by measuring the fetal metabolic effects of antenatal late preterm betamethasone and assessing the relationship of the fetal metabolic effects with neonatal hypoglycemia. STUDY DESIGN:: This was a secondary analysis of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network Antenatal Late Preterm Steroids trial, a randomized trial of antenatal betamethasone vs placebo in participants with threatened late preterm birth (2010–2015). Motherneonate dyads with stored umbilical cord blood plasma were included. Major congenital anomalies were excluded. C-peptide, insulin, leptin, and insulin-like growth factor binding protein 1 (IGFBP-1) were measured in the umbilical cord blood plasma and compared between the betamethasone and placebo groups. Multivariable generalized linear regression estimated the association between the betamethasone and biomarker levels. Subsequently, the associations between the fetal biomarkers and neonatal hypoglycemia (glucose<40 mg/dL) were investigated with multivariable logistic regression. This secondary analysis was approved by The University of North Carolina at Chapel Hill Institutional Review Board. All the tests were two-tailed, and statistical significance was defined as P<.05. RESULTS:: Of 2,831 participants in the primary trial, 203 met the inclusion criteria for this analysis: 106 (52%) were exposed to betamethasone, and 97 (48%) were exposed to placebo. A total of 173 (85%) participants delivered preterm, and 23 (11%) had gestational diabetes mellitus. The baseline characteristics were similar between the groups (Supplemental Table 1). Overall, 61 (30%) neonates had hypoglycemia: 35 (33%) were exposed to betamethasone and 26 (27%) were exposed to a placebo. Betamethasone exposure was associated with higher levels of C-peptide, insulin, and leptin but not of IGFBP-1 (Figure). There was no effect modification by gestational diabetes, but there was effect modification by the duration of time from study drug administration to delivery, whereby the associations between betamethasone and C-peptide, insulin, and leptin were the strongest among participants who delivered between 12 to 24 hours after study drug administration (Supplemental Table 2). Fetal C-peptide and insulin levels of >90th percentile, were associated with higher odds of neonatal hypoglycemia (adjusted odds ratio 3.16, 95% confidence interval 1.08–9.24 and adjusted odds ratio 6.42, 95% confidence interval 2.11–19.60, respectively; Supplemental Table 3). CONCLUSION:: Betamethasone given in the late preterm period is associated with fetal metabolic alterations such as hyperinsulinemia, and these alterations are associated with 3- to 6-fold higher odds of neonatal hypoglycemia. Although the results of this analysis warrant further validation, the mechanism of late preterm steroid-induced neonatal hypoglycemia may be similar to that observed in neonates born to pregnant people with diabetes mellitus. Further research targeting the fetal metabolic effects demonstrated here is needed to determine if the increased risk of neonatal hypoglycemia after late preterm steroids can be prevented.
引用
- Battarbee AN, Sandoval GJ, Gyamfi-Bannerman C, et al. Mechanism of neonatal hypoglycemia after late preterm steroids: are fetal metabolic effects responsible? Am J Obstet Gynecol. 2022. PMID: 35364060. doi:10.1016/j.ajog.2022.03.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。